Remove Angina Remove Coronary Artery Disease Remove Preserved Ejection Fraction
article thumbnail

Highlights of ACC 2024

Cardiology Update

STEP-HFpEF DM 5 ( NCT04916470 ) explored the effects of semaglutide in obesity-related HF with preserved ejection fraction (HFpEF) and type 2 diabetes. The primary endpoint consisted of a composite of all-cause mortality, MI, stroke, coronary revascularization, or hospitalization for unstable angina.

Angina 52
article thumbnail

What Cardiometabolic Clinicians Can Be Thankful For This Year

Cardiometabolic Health Congress

Heart Failure Management : The FINEARTS-HF trial focused on the efficacy of finerenone, an aldosterone antagonist, in reducing heart failure hospitalizations and cardiovascular mortality among patients with preserved ejection fraction (HFpEF).